Curemark Adds Two Autism Trial Sites in California

Curemark, LLC, (, a drug research and development company focused on the treatment of neurological diseases, announced that it has added two sites in California to its Phase III clinical trial program for CM-AT, the company’s autism treatment. The new sites are the University of California San Francisco (UCSF) and the Neuropsychiatric Research Center of Orange County (NRC) in Santa Ana. Curemark opened CM-AT clinical trial enrollment at the UC Davis MIND Institute in Sacramento earlier this year. The company {Read More}